Loading...

Sage Therapeutics

DB:SG7
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SG7
DB
$8B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. The last earnings update was 59 days ago. More info.


Add to Portfolio Compare Print
  • Sage Therapeutics has significant price volatility in the past 3 months.
SG7 Share Price and Events
7 Day Returns
-4.9%
DB:SG7
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
4.4%
DB:SG7
-10.6%
DE Biotechs
-6.2%
DE Market
SG7 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sage Therapeutics (SG7) -4.9% -1.8% 19.9% 4.4% 312.1% -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • SG7 outperformed the Biotechs industry which returned -10.6% over the past year.
  • SG7 outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
SG7
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Sage Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Sage Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Sage Therapeutics.

DB:SG7 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 16 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:SG7
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:SG7 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Sage Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:SG7 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -542.05 Analyst x4 -502.01
2020 -533.95 Analyst x4 -457.99
2021 -431.30 Analyst x3 -342.61
2022 -510.16 Est @ 18.29% -375.33
2023 527.20 Analyst x2 359.21
2024 595.04 Est @ 12.87% 375.49
2025 649.05 Est @ 9.08% 379.32
2026 690.72 Est @ 6.42% 373.86
2027 722.25 Est @ 4.56% 362.05
2028 745.81 Est @ 3.26% 346.25
Present value of next 10 years cash flows $518.24
DB:SG7 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $745.81 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$9,648.68
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $9,648.68 ÷ (1 + 7.98%)10
$4,479.44
DB:SG7 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $518.24 + $4,479.44
$4,997.67
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,997.67 / 50.93
$98.14
DB:SG7 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:SG7 represents 0.85874x of NasdaqGM:SAGE
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.85874x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 98.14 x 0.85874
€84.27
Value per share (EUR) From above. €84.27
Current discount Discount to share price of €141.46
= -1 x (€141.46 - €84.27) / €84.27
-67.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Sage Therapeutics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sage Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sage Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:SG7 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-8.08
NasdaqGM:SAGE Share Price ** NasdaqGM (2019-04-18) in USD $164.73
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sage Therapeutics.

DB:SG7 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SAGE Share Price ÷ EPS (both in USD)

= 164.73 ÷ -8.08

-20.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sage Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Sage Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Sage Therapeutics's expected growth come at a high price?
Raw Data
DB:SG7 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -20.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts
38.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sage Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sage Therapeutics's assets?
Raw Data
DB:SG7 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $18.40
NasdaqGM:SAGE Share Price * NasdaqGM (2019-04-18) in USD $164.73
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:SG7 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SAGE Share Price ÷ Book Value per Share (both in USD)

= 164.73 ÷ 18.40

8.95x

* Primary Listing of Sage Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sage Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Sage Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sage Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sage Therapeutics expected to perform in the next 1 to 3 years based on estimates from 16 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sage Therapeutics expected to grow at an attractive rate?
  • Sage Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Sage Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Sage Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:SG7 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:SG7 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts 38.6%
DB:SG7 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 16 Analysts 50.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:SG7 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:SG7 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,637 462 294 6
2022-12-31 918 97 171 9
2021-12-31 479 -339 -316 11
2020-12-31 135 -484 -571 16
2019-12-31 15 -516 -628 15
DB:SG7 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 90 -261 -373
2018-09-30 90 -218 -284
2018-06-30 90 -184 -235
2018-03-31 -243 -288
2017-12-31 -219 -270
2017-09-30 -194 -257
2017-06-30 -179 -221
2017-03-31 -146 -185
2016-12-31 -119 -159
2016-09-30 -103 -132
2016-06-30 -92 -118
2016-03-31 -84 -108

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sage Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Sage Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:SG7 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below

All data from Sage Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SG7 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 25.29 25.29 25.29 1.00
2022-12-31 10.04 13.50 6.57 2.00
2021-12-31 -7.18 2.32 -13.96 8.00
2020-12-31 -11.11 -6.65 -13.87 13.00
2019-12-31 -12.90 -10.08 -14.53 12.00
DB:SG7 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -8.08
2018-09-30 -6.38
2018-06-30 -5.57
2018-03-31 -7.22
2017-12-31 -7.09
2017-09-30 -6.87
2017-06-30 -6.09
2017-03-31 -5.31
2016-12-31 -4.75
2016-09-30 -4.20
2016-06-30 -3.89
2016-03-31 -3.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sage Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Sage Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sage Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sage Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sage Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sage Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sage Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sage Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Sage Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sage Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SG7 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 90.27 -372.88 201.40
2018-09-30 90.00 -283.92 145.27 210.28
2018-06-30 90.00 -234.72 107.66 210.28
2018-03-31 -287.94 79.45 214.35
2017-12-31 -270.12 62.88
2017-09-30 -256.60 57.69 42.00
2017-06-30 -220.68 50.60 71.08
2017-03-31 -185.22 44.55 142.38
2016-12-31 -158.99 39.41
2016-09-30 -131.65 33.27 99.13
2016-06-30 -117.89 30.88 87.53
2016-03-31 -108.17 28.43 80.04
2015-12-31 -94.50 25.29 69.36
2015-09-30 -78.29 20.47 57.93
2015-06-30 -64.12 16.74 47.05
2015-03-31 -46.86 12.09 32.83
2014-12-31 -36.11 9.71 24.10
2014-09-30 -29.47 7.50 19.67
2014-06-30 -24.13 5.74 16.47
2014-03-31 -21.02 4.73 15.95
2013-12-31 -18.29 3.92 14.36
2012-12-31 -9.64 2.40 7.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sage Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sage Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sage Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sage Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sage Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sage Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sage Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sage Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sage Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sage Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Sage Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sage Therapeutics Company Filings, last reported 3 months ago.

DB:SG7 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 862.97 0.00 922.78
2018-09-30 988.51 0.00 1,021.40
2018-06-30 1,077.76 0.00 1,092.43
2018-03-31 1,059.28 0.00 1,083.51
2017-12-31 475.48 0.00 518.85
2017-09-30 200.05 0.00 243.45
2017-06-30 260.30 0.00 285.93
2017-03-31 318.45 0.00 342.56
2016-12-31 368.52 0.00 397.48
2016-09-30 413.74 0.00 431.27
2016-06-30 257.21 0.00 272.30
2016-03-31 287.50 0.00 299.68
2015-12-31 173.70 0.00 186.75
2015-09-30 198.10 0.00 204.88
2015-06-30 217.45 0.00 224.23
2015-03-31 106.51 0.00 113.16
2014-12-31 121.89 0.00 127.77
2014-09-30 132.92 0.00 136.73
2014-06-30 47.68 0.00 49.13
2014-03-31 53.65 0.00 55.43
2013-12-31 6.17 0.00 8.07
2012-12-31 1.58 0.00 2.80
  • Sage Therapeutics has no debt.
  • Sage Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sage Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Sage Therapeutics has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 38.7% each year.
X
Financial health checks
We assess Sage Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sage Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sage Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sage Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Sage Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sage Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sage Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:SG7 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:SG7 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sage Therapeutics has not reported any payouts.
  • Unable to verify if Sage Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sage Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sage Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Sage Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Sage Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sage Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sage Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sage Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeff Jonas
COMPENSATION $5,748,355
AGE 65
TENURE AS CEO 5.7 years
CEO Bio

Dr. Jeffrey M. Jonas, M.D., also known as Jeff, has been the President and Chief Executive Officer of Sage Therapeutics, Inc. since joined it in August 2013. Dr. Jonas has 20 years of extensive experience on both the science and business sides of the pharmaceutical and healthcare industries. Dr. Jonas served as Chief Medical Officer and Vice President Clinical Development at Pharmacia & Upjohn Company, LLC. Dr. Jonas served as the President of Regenerative Medicine (RM) Business at Shire plc since November 15, 2012. Dr. Jonas served as the President of Shire's Regenerative Medicine (RM) business at Advanced BioHealing, Inc. since November 15, 2012. He served as Senior Vice President of research and development - pharmaceuticals business at Shire plc since August 2008. Dr. Jonas served as an Executive Vice President of ISIS Pharmaceuticals Inc., from February 1, 2007 to July 21, 2008. He led Clinical Development, Preclinical Development, Regulatory Affairs and Quality Assurance and Compliance at Isis. He was broadly responsible for the entire pipeline, both partnered and unpartnered and contribute to portfolio management of Isis. Dr. Jonas served as Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and was responsible for Clinical Development, Medical Affairs, Pharmacovigilence and External Scientific Affairs since 2006. He joined Forest in 2003 as Vice President of Central Nervous System Area and its Senior Vice President of Clinical Development since 2005. His initial experience in the pharmaceutical industry began in 1991 at Upjohn Laboratories initially as Director of Psychopharmacology and Vice President of Worldwide Pharmaceutical Regulatory Affairs after several promotions ultimately as Chief Medical Officer & Vice President of Clinical Development. He was responsible for numerous successful INDs and NDAs for drugs in a wide range of therapeutic classes. Dr. Jonas founded AVAX Technologies Inc. and served as its Chief Executive Officer and President until February 28, 2001. During his tenure, he led AVAX through several successful financings, including an initial public offering in 1997. In 2001, he founded Evogen, Inc. e served as Chairman, President and Chief Technology Officer of Evogen, Inc. He has been a Director of Sage Therapeutics, Inc. since August 2013. He has been a Director of Decibel Therapeutics, Inc. since December 2015. He has been a Director of National Pharmaceutical Council since August 03, 2011. He served as Independent Director at Cara Therapeutics, Inc. He served as Director of AVAX Technologies since 1998. He served as Chief Resident in psychopharmacology at McClean Hospital, Harvard Medical School. Dr. Jonas has published more than 70 scientific papers and chapters and has received a number of awards. He is the author of more than 100 books, scientific articles and abstracts and has given many academic, business and industry presentations. He is a successful entrepreneur. Dr. Jonas received his M.D. from Harvard Medical School in 1979 and completed a residency in psychiatry at Harvard. Dr. Jonas earned his B.A., summa cum laude in Biology and English from Amherst College.

CEO Compensation
  • Jeff's compensation has increased whilst company is loss making.
  • Jeff's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Sage Therapeutics management team in years:

4.6
Average Tenure
56
Average Age
  • The tenure for the Sage Therapeutics management team is about average.
Management Team

Jeff Jonas

TITLE
CEO, President & Director
COMPENSATION
$6M
AGE
65
TENURE
5.7 yrs

Kimi Iguchi

TITLE
CFO & Treasurer
COMPENSATION
$2M
AGE
56
TENURE
6.1 yrs

Anne Cook

TITLE
Senior VP
COMPENSATION
$2M
AGE
56
TENURE
3.6 yrs

Steve Kanes

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
53
TENURE
5.8 yrs

Mike Cloonan

TITLE
Chief Business Officer
COMPENSATION
$10M
AGE
47
TENURE
2 yrs

Heinrich Schlieker

TITLE
Senior Vice President of Technical Operations
TENURE
3.6 yrs

Al Robichaud

TITLE
Chief Scientific Officer
COMPENSATION
$1M
AGE
57
TENURE
7.4 yrs

Paul Cox

TITLE
Senior Director of Investor Relations

Erin Lanciani

TITLE
Senior Vice President of People & Organizational Strategy
AGE
49

Amy Schacterle

TITLE
Senior Vice President of Regulatory Affairs & Quality Assurance
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the Sage Therapeutics board of directors in years:

4.9
Average Tenure
58
Average Age
  • The tenure for the Sage Therapeutics board of directors is about average.
Board of Directors

Kevin Starr

TITLE
Chairman
COMPENSATION
$748K
AGE
55

Jeff Jonas

TITLE
CEO, President & Director
COMPENSATION
$6M
AGE
65
TENURE
5.7 yrs

Jim Frates

TITLE
Director
COMPENSATION
$729K
AGE
51
TENURE
4.9 yrs

Mike Cola

TITLE
Director
COMPENSATION
$731K
AGE
58
TENURE
4.6 yrs

Geno Germano

TITLE
Director
COMPENSATION
$716K
AGE
57
TENURE
2.8 yrs

Steve Paul

TITLE
Founder & Director
COMPENSATION
$726K
AGE
67
TENURE
7.6 yrs

Jim Audia

TITLE
Member of Scientific Advisory Board
AGE
62

David Farb

TITLE
Member of Scientific Advisory Board

Christine Marx

TITLE
Member of Scientific Advisory Board

A. Morrow

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Sage Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sage Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company’s product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Details
Name: Sage Therapeutics, Inc.
SG7
Exchange: DB
Founded: 2010
$7,459,533,032
50,925,991
Website: http://www.sagerx.com
Address: Sage Therapeutics, Inc.
215 First Street,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SAGE Common Stock Nasdaq Global Market US USD 21. Jul 2014
DB SG7 Common Stock Deutsche Boerse AG DE EUR 21. Jul 2014
BST SG7 Common Stock Boerse-Stuttgart DE EUR 21. Jul 2014
Number of employees
Current staff
Staff numbers
637
Sage Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 21:56
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/02/19
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.